Discovery of novel anti-proliferative compounds against A549 cells by virtual screening

Chem-Bio Informatics Journal

Volumn 10, Issue 1, 2010, Pages 46-60

  Babu, P Ajay ^a,b   Narasu, Mangamoori L ^b   Kolli, Srinivas ^c  

^a Translational Research Institute of Molecular Sciences TRIMS   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^c Sri Venkateswara College of Pharmacy   (India)

Author keywords

A549; Apoptosis; Binding affinity; Cross docking; MTT assay; ZINC database

Indexed keywords

EID: 77953178246     PISSN: 13476297     EISSN: 13470442     Source Type: Journal    
DOI: 10.1273/cbij.10.46     Document Type: Article

References (26)

1. A.W. Murray, Recycling the cell cycle: cyclins revisited, Cell, 116, 221-234 (2004).
2. M. Hatakeyama and R.A. Weinberg, The role of RB in cell cycle control, Prog Cell Cycle Res, 1, 9-19 (1995).
3. S. Grant and J.D. Roberts, The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy, Drug Resist Updat, 6, 15-26 (2003).
4. T.oble, Structure-based design of cyclin-dependent kinase inhibitors, Pharmacol Ther, 93, 125-133 (2002).
5. P.A. Babu, M.L. Narasu and K. Srinivas, Pyridines, pyridazines and guanines as CDK2 inhibitors: a review, Arkivoc, ii, 247-265 (2007).
6. J.J. Irwin and B.K. Shoichet, ZINC--a free database of commercially available compounds for virtual screening, J Chem Inf Model, 45, 177-182 (2005).
7. P.A. Babu, D.J. Smiles, M.L. Narasu and K. Srinivas, Identification of Novel CDK2 Inhibitors by QSAR and Virtual Screening Procedures, QSAR & Comb Sci, 27, 1362-1373 (2008).
8. C.M. Richardson, C.L. Nunns, D.S. Williamson, M.J. Parratt, P. Dokurno, R. Howes, J. Borgognoni, M.J. Drysdale, H. Finch, R.E. Hubbard, P.S. Jackson, P. Kierstan, G. Lentzen, J. D. Moore, J. B. Murray, H. Simmonite, A.E. Surgenor and C.J. Torrance, Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping, Bioorg Med Chem Lett, 17, 3880-3885 (2007).
9. G. Jones, P. Willett, R.C. Glen, A.R. Leach and R. Taylor, Development and validation of a genetic algorithm for flexible docking, J Mol Biol, 267, 727-748 (1997).
10. D.B. Kitchen, H. Decornez, J.R. Furr and J. Bajorath, Docking and scoring in virtual screening for drug discovery: methods and applications, Nat Rev Drug Discov, 3, 935-949 (2004).
11. R. Wang, Y. Lu and S. Wang, Comparative Evaluation of 11 Scoring Functions for Molecular Docking, J Med Chem, 46, 2287-2303 (2003).
12. P.S. Charifson, J.J. Corkery, M.A. Murcko and W.P. Walters, Consensus Scoring: A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins, J Med Chem, 42, 5100-5109 (1999).
13. Z. Zsoldos, D. Reid, A. Simon, S.B. Sadjad and A.P. Johnson, eHiTS: a new fast, exhaustive flexible ligand docking system, J Mol Graph Model, 26, 198-212 (2007).
14. R. Thomsen and M.H. Christensen, MolDock: a new technique for high-accuracy molecular docking, J Med Chem, 49, 3315-3321 (2006).
15. R. Wang, L. Lai and S. Wang, Further development and validation of empirical scoring functions for structure-based binding affinity prediction, J Comput Aided Mol Des, 16, 11-26 (2002).
16. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, J Immunol Methods, 65, 55-63 (1983).
17. P.K. Gadakar, S. Phukan, M.D. Prasanna and V.N. Balaji, Enrichment of potent GSK-3b Inhibitors from docking studies in the enzyme active site, Current Sci, 93, 1100-1107 (2007).
18. P.K. Gadakar, S. Phukan, M.D. Prasanna and V.N. Balaji, Pose prediction accuracy in docking studies and enrichment of actives in the active site of GSK-3beta, J Chem Inf Model 47, 1446-1459 (2007).
19. V.A. Ilyin, A. Abyzov and C.M. Leslin, Structural alignment of proteins by a novel TOPOFIT method, as a superimposition of common volumes at a topomax point, Protein Sci, 13, 1865-1874 (2004).
20. C.A. Lipinski, Drug-like properties and the causes of poor solubility and poor permeability, J Pharmacol Toxicol Methods, 44, 235-249 (2000).
21. D.K. Gehlhaar, G. Verkhivker, P.A. Rejto, D.B. Fogel, L.J. Fogel and S.T. Freer, Docking Conformationally Flexible Small Molecules into a Protein Binding Site through Evolutionary Programming, In: J.R. McDonnell, R.G. Reynolds, D.B. Fogel (Eds.) Proceedings of the Fourth Annual Conference on Evolutionary Programming, MIT Press, Cambridge, Massachusetts, 615-627 (1995).
22. J.M. Yang and C.C. Chen, GEMDOCK: A Generic Evolutionary Method for Molecular Docking, Proteins, 55, 288-304 (2004).
23. R.D. Clark, A. Strizhev, J.M. Leonard, J.F. Blake and J.B. Matthew, Consensus scoring for ligand/protein interactions, J Mol Graph Model, 20, 281-295 (2002).
24. C.A. Lipinski, F. Lombardo, B.W. Dominy and P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv Drug Deliv Rev, 23, 3-25 (1997).
25. A.S. Formagio, L.T. Tonin, M.A. Foglio, C. Madjarof, J.E. de Carvalho, W.F. da Costa, F.P. Cardoso and M. H. Sarragiotto, Synthesis and antitumoral activity of novel 3-(2-substituted-1,3,4-oxadiazol-5-yl) and 3-(5-substituted-1,2,4-triazol-3-yl) β-carboline derivatives, Bioorg Med Chem, 16, 9660-9667 (2008).
26. R. Lesyk, O. Vladzimirska, S. Holota, L. Zaprutko and A. Gzella, New 5-substituted thiazolo[3,2-b][1,2,4]triazol-6-ones: synthesis and anticancer evaluation, Eur J Med Chem, 42,641-648 (2007).